Powered by

Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results

Mar 01, 2017 - Business Wire
Board and Executive Moves-Mergers and Acquisitions

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2016.

"2016 was a year of progress and learning for Juno and the cancer immunotherapy field. We continue to experience encouraging signs of clinical benefit in our trial addressing NHL, but we also recognize the unfortunate and unexpected tox...